
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8505164/publications.pdf Version: 2024-02-01



Ρενατά Οδεκονδ:

| # | Article | IF | CITATIONS |
|----|---|------------------------|------------|
| 1 | 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104. | 2.2 | 6,826 |
| 2 | 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219. | 2.2 | 5,681 |
| 3 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention | 2.2 | 5,247 |
| 4 | Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet, The, 2017, 390, 2627-2642. | 13.7 | 5,010 |
| 5 | 2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187. | 0.5 | 4,778 |
| 6 | 2013 ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension, 2013, 31, 1281-1357. | 0.5 | 4,251 |
| 7 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine, 2017, 376, 1713-1722. | 27.0 | 4,179 |
| 8 | Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet, The, 2016, 387, 1377-1396. | 13.7 | 3,941 |
| 9 | National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet, The, 2011, 377, 557-567. | 13.7 | 3,476 |
| 10 | National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet, The, 2011, 378, 31-40. | 13.7 | 3,019 |
| 11 | Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants. Lancet, The, 2016, 387, 1513-1530. | 13.7 | 2,842 |
| 12 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337. | 2.2 | 2,517 |
| 13 | European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq1 | . 0:7 84314 | 47gB1/Over |
| 14 | ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 3147-3197. | 2.2 | 1,694 |
| 15 | Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19·1 million participants. Lancet, The, 2017, 389, 37-55. | 13.7 | 1,667 |
| 16 | 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536. | 2.2 | 1,617 |
| 17 | European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Heart Journal, 2003. 24. 1601-1610. | 2.2 | 1,588 |
| 18 | 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241. | 2.2 | 1,396 |

| # | Article | IF | CITATIONS |
|----|--|--------------|-------------------------|
| 19 | Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, The, 2021, 398, 957-980. | 13.7 | 1,289 |
| 20 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension, 2009, 27, 2121-2158. | 0.5 | 1,236 |
| 21 | 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1751-1762. | 0.5 | 1,152 |
| 22 | Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. New England Journal of Medicine, 2012, 367, 2204-2213. | 27.0 | 1,145 |
| 23 | Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 | . 1 02.78843 | 14 ญ BT /Ove |
| 24 | ESHRE Guideline: management of women with premature ovarian insufficiency. Human Reproduction, 2016, 31, 926-937. | 0.9 | 916 |
| 25 | National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. Lancet, The, 2011, 377, 568-577. | 13.7 | 884 |
| 26 | Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0147601. | 2.5 | 882 |
| 27 | Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New England Journal of Medicine, 2010, 363, 905-917. | 27.0 | 791 |
| 28 | 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). Journal of Hypertension, 2013, 31, 1925-1938. | 0.5 | 789 |
| 29 | EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648. | 1.8 | 772 |
| 30 | Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2011, 364, 907-917. | 27.0 | 741 |
| 31 | Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Heart Journal, 2009, 30, 2769-2812. | 2.2 | 735 |
| 32 | National, regional, and global trends in adult overweight and obesity prevalences. Population Health Metrics, 2012, 10, 22. | 2.7 | 730 |
| 33 | Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031. | 27.0 | 641 |
| 34 | Hypertension. Nature Reviews Disease Primers, 2018, 4, 18014. | 30.5 | 636 |
| 35 | Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. Journal of Hypertension, 2009, 27, 1719-1742. | 0.5 | 620 |
| 36 | Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment. Lancet Diabetes and Endocrinology,the, 2014, 2, 634-647. | 11.4 | 591 |

| # | Article | IF | CITATIONS |
|----|--|--------------------|-------------|
| 37 | The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis, 2015, 241, 507-532. | 0.8 | 587 |
| 38 | 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Pressure, 2014, 23, 3-16. | 1.5 | 565 |
| 39 | Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835. | 1.8 | 558 |
| 40 | A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nature Genetics, 2019, 51, 957-972. | 21.4 | 549 |
| 41 | Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020. | 27.0 | 526 |
| 42 | Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539. | 27.0 | 510 |
| 43 | National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3·O million participants. Lancet, The, 2011, 377, 578-586. | 13.7 | 445 |
| 44 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis, 2012, 223, 1-68. | 0.8 | 414 |
| 45 | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). European Journal of Preventive Cardiology, 2012, 19, 585-667. | 1.8 | 359 |
| 46 | 2013 ESH/ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2013, 22, 193-278. | 1.5 | 355 |
| 47 | Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure, 2009, 18, 308-347. | 1.5 | 351 |
| 48 | Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) Tj ETQq0 | 0 Q. 8gBT / | Oværbock 10 |
| 49 | Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043. | 27.0 | 299 |
| 50 | European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis, 2007, 194, 1-45. | 0.8 | 292 |
| 51 | 2007 ESHâ€ESC Guidelines for the management of arterial hypertension. Blood Pressure, 2007, 16, 135-232. | 1.5 | 292 |
| 52 | Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137. | 1.7 | 263 |
| 53 | Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. Nature Genetics, 2019, 51, 1459-1474. | 21.4 | 251 |
| 54 | Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. European Heart Journal, 2013, 34, 2149-2157. | 2.2 | 225 |

| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 55 | European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine, 2012, 19, 403-488. | 1.7 | 224 |
| 56 | Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Human Reproduction, 2000, 15, 785-789. | 0.9 | 223 |
| 57 | 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115. | 1.8 | 220 |
| 58 | The Global Cardiovascular Risk Transition. Circulation, 2013, 127, 1493-1502. | 1.6 | 205 |
| 59 | European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation. 2003. 10. S1-S10. | 2.8 | 205 |
| 60 | A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes and Endocrinology,the, 2015, 3, 339-355. | 11.4 | 185 |
| 61 | European guidelines on cardiovascular disease prevention in clinical practice <sbt>Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis, 2004, 173, 379-389.</sbt> | 0.8 | 184 |
| 62 | Hypertension and atrial fibrillation. Journal of Hypertension, 2012, 30, 239-252. | 0.5 | 177 |
| 63 | Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. European Heart Journal, 2011, 32, 1424-1431. | 2.2 | 175 |
| 64 | European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, S1-S78. | 2.8 | 174 |
| 65 | European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation, 2003, 10, S1-S10. | 2.8 | 152 |
| 66 | Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331â€^288 participants. Lancet Diabetes and Endocrinology,the, 2015, 3, 624-637. | 11.4 | 139 |
| 67 | Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal, 2021, 42, 967-984. | 2.2 | 136 |
| 68 | Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis, 2010, 211, 676-681. | 0.8 | 134 |
| 69 | The metabolic syndrome in hypertension: European society of hypertension position statement. Journal of Hypertension, 2008, 26, 1891-1900. | 0.5 | 107 |
| 70 | European guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2003, 171, 145-155. | 0.8 | 106 |
| 71 | Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133. | 6.8 | 101 |
| 72 | Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes and Endocrinology,the, 2017, 5, 196-213. | 11.4 | 90 |

| # | Article | IF | CITATIONS |
|----|--|----------------------------|---------------|
| 73 | Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology, 2009, 72, 688-694. | 1.1 | 86 |
| 74 | Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2021, 28, 370-379. | 1.8 | 83 |
| 75 | Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology. European Heart Journal, 2015, 36, 1171-1177. | 2.2 | 81 |
| 76 | Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. European Journal of Preventive Cardiology, 2015, 22, 1354-1362. | 1.8 | 81 |
| 77 | Time Trends in Lifestyle, Risk Factor Control, and Use of Evidence-Based Medications in Patients With Coronary Heart Disease in Europe: Results From 3 EUROASPIRE Surveys, 1999–2013. Global Heart, 2017, 12, 315. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' The | 2.3 | 81 |
| 78 | Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQqO (| 0 0 rgBT /0 2 .2 | Dverlock 10 T |
| 79 | Prevention & Rehabilitation (EACPR). [Eur Heart J 2012;33:1635-1701, doi: 10.1093/eurheartj/ehs092]. European Heart Journal, 2012, 33, 2126-2126. Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women. Stroke, 2008, 39, 2444-2448. | 2.0 | 76 |
| 80 | Desphospho-uncarboxylated matrix Gla-protein is associated with mortality risk in patients with chronic stable vascular disease. Atherosclerosis, 2014, 235, 162-168. | 0.8 | 75 |
| 81 | Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. Journal of Hypertension, 2010, 28, 2196-2203. | 0.5 | 72 |
| 82 | Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study. European Heart Journal, 2011, 32, 218-225. | 2.2 | 70 |
| 83 | Blood pressure around the menopause: a population study. Journal of Hypertension, 2008, 26, 1976-1982. | 0.5 | 68 |
| 84 | Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient. Journal of Hypertension, 2014, 32, 1888-1897. | 0.5 | 65 |
| 85 | Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants. International Journal of Epidemiology, 2018, 47, 872-883i. | 1.9 | 65 |
| 86 | Mechanisms of hypertension in the cardiometabolic syndrome. Journal of Hypertension, 2009, 27, 441-451. | 0.5 | 63 |
| 87 | Dyslipidemia and Cardiovascular Disease in Women. Current Cardiology Reports, 2015, 17, 609. | 2.9 | 62 |
| 88 | Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Human Reproduction, 2003, 18, 980-984. | 0.9 | 59 |
| 89 | Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe. Journal of Hypertension, 2013, 31, 2018-2024. | 0.5 | 58 |
| 90 | Desphospho-uncarboxylated matrix Gla protein is associated with increased aortic stiffness in a general population. Journal of Human Hypertension, 2016, 30, 418-423. | 2.2 | 55 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | ESH-ESC Guidelines for the Management of Hypertension. Herz, 2006, 31, 331-338. | 1.1 | 52 |
| 92 | Explaining the decline in coronary heart disease mortality in the Czech Republic between 1985 and 2007. European Journal of Preventive Cardiology, 2014, 21, 829-839. | 1.8 | 52 |
| 93 | Trends in blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2000/01. Journal of Hypertension, 2004, 22, 1479-1485. | 0.5 | 51 |
| 94 | Low blood pressure during the acute period of ischemic stroke is associated with decreased survival. Journal of Hypertension, 2015, 33, 339-345. | 0.5 | 50 |
| 95 | Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Annals of Medicine, 2010, 42, 447-464. | 3.8 | 49 |
| 96 | Relationship between measures of central and general adiposity with aortic stiffness in the general population. Atherosclerosis, 2014, 235, 625-631. | 0.8 | 48 |
| 97 | The polypill in cardiovascular prevention. Journal of Hypertension, 2017, 35, 1546-1553. | 0.5 | 48 |
| 98 | Prevalence, awareness, treatment, and control of hypertension in the Czech Republic. Results of two nationwide cross-sectional surveys in 1997/1998 and 2000/2001, Czech Post-MONICA Study. Journal of Human Hypertension, 2004, 18, 571-579. | 2.2 | 45 |
| 99 | Large artery stiffness and pulse wave reflection: Results of a populationâ€based study. Blood Pressure, 2005, 14, 45-52. | 1.5 | 45 |
| 100 | Kardiovize Brno 2030, a prospective cardiovascular health study in Central Europe: Methods, baseline findings and future directions. European Journal of Preventive Cardiology, 2018, 25, 54-64. | 1.8 | 45 |
| 101 | Threshold for diagnosing hypertension by automated office blood pressure using random sample population data. Journal of Hypertension, 2016, 34, 2180-2186. | 0.5 | 43 |
| 102 | The Obesity Paradox and Survivors of Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1443-1450. | 1.6 | 42 |
| 103 | Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. ELife, 2021, 10, . | 6.0 | 41 |
| 104 | The association between low 25-hydroxyvitamin D and increased aortic stiffness. Journal of Human Hypertension, 2012, 26, 650-655. | 2.2 | 39 |
| 105 | Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline. Journal of Hypertension, 2014, 32, 1741-1750. | 0.5 | 39 |
| 106 | Arterial hypertension as a public health issue in the Czech Republic. Blood Pressure, 2005, 14, 25-28. | 1.5 | 38 |
| 107 | Lower-extremity arterial stiffness vs. aortic stiffness in the general population. Hypertension Research, 2013, 36, 718-724. | 2.7 | 38 |
| 108 | 30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 – 2016/17. PLoS ONE, 2020, 15, e0232845. | 2.5 | 34 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. Journal of Human Hypertension, 2006, 20, 267-271. | 2.2 | 33 |
| 110 | Arterial stiffness parameters: How do they differ?. Atherosclerosis, 2013, 231, 359-364. | 0.8 | 33 |
| 111 | Changes in Hypertension Prevalence, Awareness, Treatment, and Control in High-, Middle-, and Low-Income Countries: An Update. Current Hypertension Reports, 2016, 18, 62. | 3.5 | 33 |
| 112 | Educational level and risk profile and risk control in patients with coronary heart disease. European Journal of Preventive Cardiology, 2016, 23, 881-890. | 1.8 | 33 |
| 113 | Risk stratification in cardiovascular disease primary prevention – scoring systems, novel markers, and imaging techniques. Fundamental and Clinical Pharmacology, 2012, 26, 163-174. | 1.9 | 32 |
| 114 | Relation of central and brachial blood pressure to left ventricular hypertrophy. The Czech Post-MONICA Study. Journal of Human Hypertension, 2012, 26, 14-19. | 2.2 | 31 |
| 115 | Valsartan and atenolol in patients with severe essential hypertension. Journal of Human Hypertension, 1998, 12, 563-567. | 2.2 | 30 |
| 116 | Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. International Journal of Cardiology, 2019, 286, 214-219. | 1.7 | 30 |
| 117 | The prevalence of major cardiovascular risk factors in the Czech population in 2006-2009. The Czech post-MONICA study. Cor Et Vasa, 2011, 53, 220-229. | 0.1 | 27 |
| 118 | Large artery stiffness and carotid flow pulsatility in stroke survivors. Journal of Hypertension, 2014, 32, 1097-1103. | 0.5 | 26 |
| 119 | Quality of Life Predictors in Chronic Stable Post-Stroke Patients and Prognostic Value of SF-36 Score as a Mortality Surrogate. Translational Stroke Research, 2015, 6, 375-383. | 4.2 | 26 |
| 120 | Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT. Journal of Hypertension, 2016, 34, 393-396. | 0.5 | 26 |
| 121 | The low expression of circulating microRNA-19a represents an additional mortality risk in stable patients with vascular disease. International Journal of Cardiology, 2019, 289, 101-106. | 1.7 | 26 |
| 122 | GuÃa de práctica clÃnica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Revista Espanola De Cardiologia, 2013, 66, 880.e1-880.e64. | 1.2 | 24 |
| 123 | The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease. International Journal of Cardiology, 2016, 203, 916-922. | 1.7 | 24 |
| 124 | Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. International Journal of Cardiology, 2018, 272, 20-25. | 1.7 | 24 |
| 125 | Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 384-393. | 3.0 | 24 |
| 126 | Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia, 2021, 64, 2012-2025. | 6.3 | 24 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Reference values of cardio-ankle vascular index in a random sample of a white population. Journal of Hypertension, 2017, 35, 2238-2244. | 0.5 | 23 |
| 128 | Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population. Hypertension Research, 2016, 39, 266-271. | 2.7 | 22 |
| 129 | Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. European Journal of Epidemiology, 2019, 34, 247-258. | 5.7 | 22 |
| 130 | Exploring potential mortality reductions in 9 European countries by improving diet and lifestyle: A modelling approach. International Journal of Cardiology, 2016, 207, 286-291. | 1.7 | 19 |
| 131 | N-terminal pro B-type natriuretic peptide as prognostic marker for mortality in coronary patients without clinically manifest heart failure. European Journal of Epidemiology, 2009, 24, 363-368. | 5.7 | 18 |
| 132 | Is Diabetes Mellitus a Heart Disease Equivalent in Women?. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 164-170. | 2.2 | 18 |
| 133 | Cyclosporin-induced hypertension. Journal of Hypertension, 2001, 19, 2283-2285. | 0.5 | 18 |
| 134 | Preclinical atherosclerosis and cardiovascular events: Do we have a consensus about the role of preclinical atherosclerosis in the prediction of cardiovascular events?. Atherosclerosis, 2022, 348, 25-35. | 0.8 | 18 |
| 135 | Positive effects of antihypertensive treatment on aortic stiffness in the general population. Hypertension Research, 2014, 37, 64-68. | 2.7 | 17 |
| 136 | Synergistic effect of low K and D vitamin status on arterial stiffness in a general population. Journal of Nutritional Biochemistry, 2017, 46, 83-89. | 4.2 | 16 |
| 137 | A Comparison of the Effects of Mibefradil and Atenolol on Regression of Left Ventricular Hypertrophy in Hypertensive Patients. Cardiology, 1998, 89, 263-270. | 1.4 | 15 |
| 138 | A high ankle-brachial index is associated with increased aortic pulse wave velocity: the Czech post-MONICA study. European Journal of Cardiovascular Prevention and Rehabilitation, 2011, 18, 790-796. | 2.8 | 15 |
| 139 | Current and past smoking patterns in a Central European urban population: a cross-sectional study in a high-burden country. BMC Public Health, 2016, 16, 571. | 2.9 | 15 |
| 140 | Comparison of three office blood pressure measurement techniques and their effect on hypertension prevalence in the general population. Journal of Hypertension, 2020, 38, 656-662. | 0.5 | 15 |
| 141 | Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. Journal of Human Hypertension, 2000, 14, 347-354. | 2.2 | 14 |
| 142 | The Impact of Blood Pressure and Visceral Adiposity on the Association of Serum Uric Acid With Albuminuria in Adults Without Full Metabolic Syndrome. American Journal of Hypertension, 2016, 29, 1335-1342. | 2.0 | 14 |
| 143 | Hypertension and Reproduction. Current Hypertension Reports, 2020, 22, 29. | 3.5 | 14 |
| 144 | The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?. Journal of Human Hypertension, 2021, 35, 240-249. | 2.2 | 14 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population?. Hypertension Research, 2021, 44, 518-527. | 2.7 | 14 |
| 146 | The quality of secondary prevention of coronary heart disease in Czech patients in the EURO-ASPIRE III survey Cor Et Vasa, 2008, 50, 156-162. | 0.1 | 13 |
| 147 | Synergistic effect of angiotensin II type 1 receptor and endothelial nitric oxide synthase gene polymorphisms on arterial stiffness. Journal of Human Hypertension, 2008, 22, 111-118. | 2.2 | 12 |
| 148 | GuÃa de práctica clÃnica de la ESC para el tratamiento de las enfermedades cardiovasculares durante el embarazo. Revista Espanola De Cardiologia, 2012, 65, 171.e1-171.e44. | 1.2 | 12 |
| 149 | Comparison of Noninvasive Assessments of Central Blood Pressure Using General Transfer Function and Late Systolic Shoulder of the Radial Pressure Wave. American Journal of Hypertension, 2014, 27, 162-168. | 2.0 | 12 |
| 150 | Blood pressure, endothelial function and circulating endothelin concentrations in liver transplant recipients. Journal of Hypertension, 2001, 19, 1359-1367. | 0.5 | 11 |
| 151 | Adverse Lifestyle Trends Counter Improvements in Cardiovascular Risk Factor Management in Coronary Patients. Journal of the American College of Cardiology, 2015, 66, 1634-1636. | 2.8 | 11 |
| 152 | Why is the treatment of hypertension in pregnancy still so difficult?. Expert Review of Cardiovascular Therapy, 2011, 9, 647-649. | 1.5 | 10 |
| 153 | Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients. European Journal of Internal Medicine, 2018, 47, 55-61. | 2.2 | 10 |
| 154 | The standard of secondary prevention of stroke in Czech patients in the EUROASPIRE III Study - Stroke Specific Module. Cor Et Vasa, 2008, 50, 446-454. | 0.1 | 10 |
| 155 | Blood pressure control and risk profile in poststroke survivors. Journal of Hypertension, 2015, 33, 2107-2114. | 0.5 | 9 |
| 156 | Tobacco smoking strongly modifies the association of prothrombin G20210A with undetermined stroke: Consecutive survivors and population-based controls. Atherosclerosis, 2015, 240, 446-452. | 0.8 | 9 |
| 157 | Serum Vitamin D Status, Vitamin D Receptor Polymorphism, and Glucose Homeostasis in Healthy Subjects. Hormone and Metabolic Research, 2018, 50, 56-64. | 1.5 | 9 |
| 158 | Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness. Hypertension Research, 2020, 43, 111-120. | 2.7 | 9 |
| 159 | Serum Bilirubin Concentrations and the Prevalence of Gilbert Syndrome in Elite Athletes. Sports Medicine - Open, 2022, 8, . | 3.1 | 9 |
| 160 | Update on Hypertension Management: Treatment of hypertension in patients with type 2 diabetes mellitus. Journal of Hypertension, 2006, 24, 208-210. | 0.5 | 8 |
| 161 | The metabolic syndrome in hypertension: Diagnostic and therapeutic implications. Current Hypertension Reports, 2007, 9, 305-313. | 3.5 | 8 |
| 162 | Cardiovascular Sequels of Hypertension in Pregnancy. Journal of the American Heart Association, 2018, 7, . | 3.7 | 8 |

| # | Article | IF | CITATIONS |
|-----|---|------------------|--------------|
| 163 | Mood disorders impaired quality of life but not the mortality or morbidity risk in stable coronary heart disease patients. Acta Cardiologica, 2020, 75, 667-675. | 0.9 | 8 |
| 164 | Serum Bilirubin in the Czech Population ― Relationship to the Risk of Myocardial Infarction in Males ―. Circulation Journal, 2020, 84, 1779-1785. | 1.6 | 8 |
| 165 | (The prevalence of major cardiovascular risk factors in the Czech population in 2015-2018. The Czech) Tj ETQq1 I | l 0.78431 0.1 | 4 ggBT /Over |
| 166 | Summary of the European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): Prepared by the Czech Society of Cardiology. Cor Et Vasa, 2014, 56, e169-e189. | 0.1 | 7 |
| 167 | Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry. Journal of Hypertension, 2019, 37, 2015-2023. | 0.5 | 7 |
| 168 | European Society of Hypertension Scientific Newsletter: Update on Hypertension Management: Prevention of type 2 diabetes mellitus with antihypertensive drugs. Journal of Hypertension, 2006, 24, 2478-2482. | 0.5 | 6 |
| 169 | The burden of hypertension and inadequate control in populations. Journal of Hypertension, 2006, 24, 807-809. | 0.5 | 6 |
| 170 | Availability and use of home blood pressure measurement in the Czech general population. Cor Et Vasa, 2014, 56, e158-e163. | 0.1 | 6 |
| 171 | Residual cardiovascular risk in patients with stable coronary heart disease over the last 16 years (Czech part of the EUROASPIRE I-IV surveys). Cor Et Vasa, 2014, 56, e98-e104. | 0.1 | 6 |
| 172 | The coincidence of low vitamin K status and high expression of growth differentiation factor 15 may indicate increased mortality risk in stable coronary heart disease patients. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 540-551. | 2.6 | 6 |
| 173 | Resumen Ejecutivo: GuÃa Europea de Prevención Cardiovascular en la práctica clÃnica. Revista Espanola De Salud Publica, 2004, 78, 439-456. | 0.3 | 6 |
| 174 | Prevalence and Risk of Hypertension in Renal Disease – Data from the Czech Registry of Renal Biopsies. Kidney and Blood Pressure Research, 2008, 31, 135-142. | 2.0 | 5 |
| 175 | Differential effect of metabolic syndrome on various parameters of arterial stiffness. Blood Pressure, 2015, 24, 206-211. | 1.5 | 5 |
| 176 | A comparison of secondary prevention practice inÂpoststroke and coronary heart disease patients. Public Health, 2016, 137, 64-72. | 2.9 | 5 |
| 177 | The risk profile of patients with acute coronary syndrome treated at IKEM between 2006 and 2013. Cor Et Vasa, 2017, 59, e119-e127. | 0.1 | 5 |
| 178 | Longitudinal trends in the prevalence of hyperuricaemia and chronic kidney disease in hypertensive and normotensive adults. Blood Pressure, 2020, 29, 308-318. | 1.5 | 5 |
| 179 | Reference values of retinal microcirculation parameters derived from a population random sample. Microvascular Research, 2021, 134, 104117. | 2.5 | 5 |
| 180 | Alcohol and cardiovascular disease: Position Paper of the Czech Society of Cardiology. Central European Journal of Public Health, 2019, 27, S6-S9. | 1.1 | 5 |

| # | Article | IF | CITATIONS |
|-----|---|--------------|-----------|
| 181 | European guidelines on cardiovascular disease prevention in clinical practice: past, present, and future: a need for joint forces. Journal of Hypertension, 2008, 26, 157-160. | 0.5 | 4 |
| 182 | Statins and hypertension. Journal of Hypertension, 2009, 27, 662-665. | 0.5 | 4 |
| 183 | Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population. Clinica Chimica Acta, 2011, 412, 920-924. | 1.1 | 4 |
| 184 | Tobacco use and some characteristics of tobacco users. Preliminary results of "Kardiovize Brno 2030". Cor Et Vasa, 2014, 56, e118-e127. | 0.1 | 4 |
| 185 | The DRD2/ANKK1 Taq1A polymorphism is associated with smoking cessation failure in patients with coronary heart disease. Personalized Medicine, 2015, 12, 463-473. | 1.5 | 4 |
| 186 | The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2. Maturitas, 2015, 80, 82-88. | 2.4 | 4 |
| 187 | Should 24-Hour Ambulatory Blood Pressure Monitoring Become Part of Regular Checkup in Women With Previous Preeclampsia?. Hypertension, 2018, 71, 59-60. | 2.7 | 4 |
| 188 | Uromodulin in a Pathway Between Decreased Renal Urate Excretion and Albuminuria. American Journal of Hypertension, 2019, 32, 384-392. | 2.0 | 4 |
| 189 | The prognostic importance of subclinical heart failure in stable coronary heart disease patients. Acta Cardiologica, 2020, 75, 329-336. | 0.9 | 4 |
| 190 | Which serum uric acid levels are associated with increased cardiovascular risk in the general adult population?. Journal of Clinical Hypertension, 2020, 22, 897-905. | 2.0 | 4 |
| 191 | Primary aldosteronism in a general population sample. The Czech post-MONICA study. Blood Pressure, 2020, 29, 191-198. | 1.5 | 4 |
| 192 | Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiologia Polska, 2 71, 27-118. | 2013, 0.6 | 4 |
| 193 | State of secondary prevention in Czech coronary patients in the EUROASPIRE IV study. Cor Et Vasa, 2014, 56, e105-e112. | 0.1 | 3 |
| 194 | Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey. Cardiovascular Ultrasound, 2019, 17, 22. | 1.6 | 3 |
| 195 | Systematic COronary Risk Evaluation (SCORE) and 20-year risk of cardiovascular mortality and cancer. European Journal of Internal Medicine, 2020, 79, 63-69. | 2.2 | 3 |
| 196 | The Prognostic Importance of Impaired Fasting Glycemia in Chronic Coronary Heart Disease Patients. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 29-35. | 1.2 | 3 |
| 197 | Triglycerides, remnant lipoprotein particles and preclinical atherosclerosis in the Czech population. Atherosclerosis, 1999, 144, 126-127. | 0.8 | 2 |
| 198 | Hypertension in pregnancy. Journal of Hypertension, 2000, 18, 1346-1348. | 0.5 | 2 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Agreement within Europe about antihypertensive treatment and education – results from the European Society of Hypertension questionnaire. Journal of Hypertension, 2010, 28, 1593-1594. | 0.5 | 2 |
| 200 | An inverse association between serum leptin concentration and reported alcohol intake in patients with manifest vascular disease. European Journal of Clinical Nutrition, 2010, 64, 1350-1357. | 2.9 | 2 |
| 201 | Blood Pressure-Lowering Aspects of Lipid-Lowering and Anti-Diabetic Drugs. Pharmaceuticals, 2011, 4, 1-6. | 3.8 | 2 |
| 202 | Association between endothelial NO synthase polymorphism (rs3918226) and arterial properties. Artery Research, 2013, 7, 54. | 0.6 | 2 |
| 203 | Exercise testing in hypertensive patients for assessing the cardiovascular protective potential of antihypertensive drugs. Therapeutic Advances in Cardiovascular Disease, 2013, 7, 99-108. | 2.1 | 2 |
| 204 | Hypertriglyceridemic waist increased risk of inappropriate glucose control in patients with coronary heart disease. Clinical Lipidology, 2014, 9, 515-522. | 0.4 | 2 |
| 205 | Is There Really an Association of High Circulating Adiponectin Concentration and Mortality or Morbidity Risk in Stable Coronary Artery Disease?. Hormone and Metabolic Research, 2020, 52, 861-868. | 1.5 | 2 |
| 206 | Antiplatelet and Lipid-lowering Drugs in Hypertension. European Cardiology Review, 2014, 9, 16. | 2.2 | 2 |
| 207 | Hypertension in the metabolic syndrome: summary of the new position statement of the European Society of Hypertension. Polish Archives of Internal Medicine, 2009, 119, 255-260. | 0.4 | 2 |
| 208 | Carotid intima-media thickness in young survivors of acute myocardial infarction. Experimental and Clinical Cardiology, 2012, 17, 215-20. | 1.3 | 2 |
| 209 | ESH statement on detection and punishment of abstract fraud and poster plagiarism. Blood Pressure, 2005, 14, 322-323. | 1.5 | 1 |
| 210 | T01-P-006 Prediction of diabetes in individuals with impaired fasting glucose in the Czech population in the 1997/98 to 2000/01 period. Atherosclerosis Supplements, 2005, 6, 134. | 1.2 | 1 |
| 211 | The scope of hypertension. Blood Pressure, 2005, 14, 3-5. | 1.5 | 1 |
| 212 | ESH statement on detection and punishment of abstract fraud and poster plagiarism. Journal of Hypertension, 2006, 24, 203-204. | 0.5 | 1 |
| 213 | Can blood pressure in the first trimester predict the development of gestational hypertensive disorders?. European Heart Journal, 2011, 32, 3067-3069. | 2.2 | 1 |
| 214 | The predictive potential of asymptomatic mild elevation of cardiac troponin I on mortality risk of stable patients with vascular disease. Clinical Biochemistry, 2015, 48, 353-357. | 1.9 | 1 |
| 215 | The changes of secondary prevention practice in Czech post-stroke patients between 2007 and 2012/13. Cor Et Vasa, 2016, 58, e367-e373. | 0.1 | 1 |
| 216 | Response to Letter to the Editor entitled Oxidative Stress Participates in the Associations Between Serum Uric Acid and Albuminuria in Obesity. American Journal of Hypertension, 2017, 30, e2-e3. | 2.0 | 1 |

| # | Article | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Left ventricular hypertrophy in females with hypertension is associated with a poor prognosis. International Journal of Cardiology, 2018, 258, 277-278. | 1.7 | 1 |
| 218 | Synergistic effect of sclerostin and angiotensin II receptor 1 polymorphism on arterial stiffening. Biomarkers in Medicine, 2020, 14, 173-184. | 1.4 | 1 |
| 219 | Hypertrophic remodelling of retinal arterioles in patients with congestive heart failure. ESC Heart Failure, 2021, 8, 1892-1900. | 3.1 | 1 |
| 220 | Current trends in drug treatment of hypertension. Interni Medicina Pro Praxi, 2017, 19, 10-15. | 0.0 | 1 |
| 221 | Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients. Biomarkers in Medicine, 2021, 15, 1465-1477. | 1.4 | 1 |
| 222 | The changes in achievement of target LDL-cholesterol levels between 2006 and 2017 in Czech patients with chronic coronary heart disease. Cor Et Vasa, 2019, 61, 20-27. | 0.1 | 1 |
| 223 | Title is missing!. , 2020, 15, e0232845. | | 1 |
| 224 | Mild chronic hypertension in pregnancy: to treat or wait?. Blood Pressure, 2022, 31, 121-124. | 1.5 | 1 |
| 225 | High leptin status indicates an increased risk of mortality and heart failure in stable coronary artery disease. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 2137-2146. | 2.6 | 1 |
| 226 | W11-P-004 The metabolic syndrome in a Czechpopulation random sample: A Czech post-Monica study. Atherosclerosis Supplements, 2005, 6, 57. | 1.2 | 0 |
| 227 | W16-IS-001 Assessment of global cardiovascular risk. Atherosclerosis Supplements, 2005, 6, 98. | 1.2 | Ο |
| 228 | T01-P-005 Hyperuricemia — The forgotten component of metabolic syndrome?. Atherosclerosis Supplements, 2005, 6, 134. | 1.2 | 0 |
| 229 | Introduction. Blood Pressure, 2005, 14, 2-2. | 1.5 | 0 |
| 230 | The Renin-Angiotensin System, Capri 2005. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 91-108. | 2.2 | 0 |
| 231 | Highlights from International Congress. High Blood Pressure and Cardiovascular Prevention, 2006, 13, 61-72. | 2.2 | 0 |
| 232 | Treatment of hypertension in ptients with type-2 diabetes mellitus. Blood Pressure, 2006, 15, 62-63. | 1.5 | 0 |
| 233 | WO16-OR-5 RECENT CHANGES OF RISK FACTORS OF CHD IN THE CZECH POPULATION. Atherosclerosis Supplements, 2007, 8, 17. | 1.2 | 0 |
| 234 | Hypovolaemia-induced metabolic dysfunction, mediated in part by aldosterone and angiotensin. Journal of Hypertension, 2009, 27, 2116-2117. | 0.5 | 0 |

| # | Article | IF | CITATIONS |
|-----|---|-----|-----------|
| 235 | Guidelines and research upon which guidelines are founded. Journal of Hypertension, 2013, 31, 1279-1280. | 0.5 | 0 |
| 236 | Why COLM and ACCOMPLISH study results differ. Journal of Hypertension, 2014, 32, 1967-1969. | 0.5 | 0 |
| 237 | Reply. Journal of Hypertension, 2017, 35, 2551-2552. | 0.5 | 0 |
| 238 | Arterial Hypertension and Cardiovascular Risk. , 2019, , 57-74. | | 0 |
| 239 | Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. , 2012, , 199-211. | | 0 |
| 240 | Resistant Hypertension: Definition, Prevalence, and Cardiovascular Risk. , 2013, , 1-8. | | 0 |
| 241 | Epidemiology of Hypertension and Brain Disease. Updates in Hypertension and Cardiovascular Protection, 2016, , 1-11. | 0.1 | 0 |
| 242 | Current status of secondary prevention in Czech coronary patients in the EUROASPIRE V Study. Cor Et Vasa, 2019, 61, e277-e283. | 0.1 | 0 |
| 243 | Adherence to cardiovascular prevention principles in subjects at high risk. Vnitrni Lekarstvi, 2020, 66, e5-e12. | 0.2 | 0 |
| 244 | Gender differences in secondary prevention of coronary heart disease: Far from closing the gap. International Journal of Cardiology, 2022, 355, 52-53. | 1.7 | 0 |
| 245 | Title is missing!. , 2020, 15, e0232845. | | 0 |
| 246 | Title is missing!. , 2020, 15, e0232845. | | 0 |
| 247 | Title is missing!. , 2020, 15, e0232845. | | Ο |